CAD-1 / Cadenza Bio - LARVOL DELTA

Cadenza Bio, Inc. Secures $2.44M in Oversubscribed Series Seed Financing (PRNewswire) - "Cadenza Bio, Inc...has announced the initial closing of an oversubscribed $2.44M Series Seed financing....The financing supports non-clinical safety and toxicology studies to advance Cadenza's lead development candidate, CAD-1, for treatment of Multiple Sclerosis (MS), and additionally provides funds to develop secondary indication(s)."

Financing • Immunology • Multiple Sclerosis